まとめ
肝臓疾患は,プロトロンビン (因子II抗原) のレベルと活性を低下させることにより,血液の凝固を損なう. 抗原因子IIの測定は,肝臓の合成機能と凝固病についての洞察を提供します.
科学分野:
- 肝臓病理学 肝臓病理学
- 血液学 ヘマトロジ
- バイオケミストリー バイオケミストリー
背景:
- 肝臓疾患は,血静に大きく影響する.
- 凝固病は,肝臓疾患の患者の一般的な合併症です.
研究 の 目的:
- 肝疾患の患者におけるプロトロンビン免疫反応性タンパク質 (因子II抗原) と凝固剤の活性に関するプラズマ濃度を調査する.
- 肝臓疾患における因子II抗原と因子II凝固剤の活性との関係を評価する.
- 肝臓の合成能力の指標として,因子II抗原レベルの有用性を決定する.
主な方法:
- 血プロトロンビン免疫反応性タンパク質 (II-Ag) レベルを測定する.
- 血プロトロンビン凝固剤活性 (II-CA) の決定.
- 急性肝炎と慢性肝疾患 (肝硬変) の患者からのデータの分析.
主要な成果:
- II-CAの減少は患者の62%で,II-Agの減少は46%で観察されました.
- 57%の症例で不釣り合いの減少 (II-AgがII-CAよりも多い) が認められた.
- 中度から重度の肝細胞疾患では,96%がII-CAの減少を示し,63%がII-Agの減少を示し,67%がII-CAの不均衡な減少を示した.
結論:
- プロトロンビン前駆体の合成の減少とカルボキシル化障害は,肝疾患における凝固病に寄与する.
- 循環する因子II抗原レベルの測定は,肝臓の合成能力の信頼できる指標として機能することができます.
さらに関連する動画
04:56Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
Published on: August 4, 2023
08:01The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
